RECRUITING

CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia

Talk to us

Conditions

Acute Myeloid LeukemiaRecurrent Adult Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaSecondary Acute Myeloid Leukemia

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This phase I trial tests the safety, side effects, and the best dose of anti-CD33 chimeric antigen receptor (CAR) T-Cell therapy in treating patients with acute myeloid leukemia that has come back (recurrent) or does not respond to treatment (refractory). CAR T-cell therapy is a type of treatment in which a patient or donor's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's or donor's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers.

Official Title

Phase I Study of Cellular Immunotherapy Using T Cells Lentivirally Transduced to Express a Cd33-Specific Chimeric Antigen Receptor for Patients With Cd33+ Relapsed/Refractory Acute Myeloid Leukemia

Quick Facts

Study Start:2023-12-07
Study Completion:2026-09-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05672147

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Documented informed consent of the participant and/or legally authorized representative
  2. * Assent, when appropriate, will be obtained per institutional guidelines
  3. * For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator to proceed with screening, while the request for a translated full consent is processed
  4. * Agreement to allow the use of archival tissue from diagnostic tumor biopsies
  5. * If unavailable, exceptions may be granted with Study principal investigator (PI) approval
  6. * Age: \>= 18 years
  7. * Karnofsky Performance Scale (KPS) \>= 70
  8. * Life expectancy \>= 16 weeks at the time of enrollment
  9. * Prior allogeneic transplant allowed if \> 6 months prior to study enrollment
  10. * Participant must have a confirmed diagnosis of active CD33+ AML de novo, or secondary OR participants who are at a high risk for disease recurrence
  11. * Relapsed AML is defined as patients that had a first complete response (CR) before developing recurrent disease (increased bone marrow blasts)
  12. * Refractory AML is defined as patients that have not achieved a first CR after induction chemotherapy. For patients with AML evolving from myelodysplastic syndrome, they should have completed at least one cycle of induction chemotherapy
  13. * Research participants must have bone marrow and/or peripheral blood samples available for confirmation of diagnosis of AML
  14. * CD33 positivity must be confirmed by either flow cytometry or immunohistochemistry within 90 days of study entry. Cytogenetics, flow cytometry, and molecular studies (such as FLT-3 status) will be obtained as per standard practice
  15. * Research participants who are at a high risk of disease recurrence, they must have historical bone marrow and/or peripheral blood samples available for confirmation of diagnosis of AML
  16. * No known contraindications to lymphodepleting agents, steroids, tocilizumab and/or cetuximab, or the investigational agent
  17. * Total serum bilirubin =\< 2.0 mg/dL
  18. * Participants with Gilbert syndrome may be included if their total bilirubin is =\< 3.0
  19. * Aspartate aminotransferase (AST) =\< 3 x the upper limit of normal (ULN)
  20. * Alanine aminotransferase (ALT) =\< 3 x ULN
  21. * Estimated creatinine clearance of \>= 60 mL/min per the Cockcroft-Gault formula, and the participant is not on hemodialysis
  22. * Left ventricular ejection fraction \>= 50% within 8 weeks before enrollment
  23. * Oxygen (O2) saturation \> 92% not requiring oxygen supplementation
  24. * Women of childbearing potential (WOCBP): negative urine or serum pregnancy test
  25. * If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
  26. * Agreement by females and males of childbearing potential to use an effective method of birth control or abstain from heterosexual activity for the course of the study through at least 6 months after the last dose of protocol therapy
  27. * Childbearing potential defined as not being surgically sterilized (men and women) or have not been free from menses for \> 1 year (women only)
  28. * Research participants must have a potential donor or stem cell source identified for allogeneic transplantation, either related (7/8 or 8/8 allele matched or haploidentical)
  29. * DONOR: The identified donor must be the original donor whose stem cells were used for the research participant's allogeneic hematopoietic stem cell transplantation (alloSCT)
  30. * DONOR: The donor must be HIV negative
  31. * DONOR: KPS \>= 70
  32. * DONOR: Documented body weight
  1. * Prior allogeneic transplant if \< 6 months prior to enrollment
  2. * Concurrent use of systemic steroids or chronic use of immunosuppressant medications should be stopped 28-days prior to enrollment. Recent or current use of inhaled or topical steroids in standard doses is not exclusionary. Physiologic replacement of steroids (prednisone =\< 7.5 mg/day, or equivalent doses of other corticosteroids) is allowed
  3. * Participants with active autoimmune disease, including graft versus host disease (GvHD), requiring systemic immune suppressive should be stopped 28-days prior to enrollment
  4. * Participants may not be receiving any other investigational agents and are not dependent on concurrent biological therapy, chemotherapy, or radiation therapy
  5. * With exception to Hydrea which must be stopped prior to initiation of lymphodepletion
  6. * Research participants on active systemic antifungal treatment within 8 weeks of enrollment are not eligible. However, participants on antifungal prophylaxis are eligible
  7. * Not applicable at the time of enrollment if the research participant's donor is undergoing leukapheresis
  8. * Subjects with \>= Grade 2 myelofibrosis on bone marrow biopsy
  9. * Subjects with clinically significant arrhythmia or arrhythmias not stable on medical management within two weeks of screening if the patient is undergoing leukapheresis. Patients with controlled atrial arrythmia is allowed
  10. * Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia
  11. * History of stroke or intracranial hemorrhage within 6 months prior to screening
  12. * Subjects with presence of other active malignancy, however, research participants with history of prior malignancy treated with curative intent and in complete remission are eligible
  13. * Clinically significant uncontrolled illness
  14. * Active infection requiring antibiotics
  15. * Research participants who have tested human immunodeficiency virus (HIV) positive, or have active hepatitis B or C infection based on testing performed within 4 weeks of enrollment
  16. * Active viral hepatitis
  17. * Females only: Pregnant or breastfeeding
  18. * Any other condition that would, in the Investigator's judgment, contraindicate the subject's participation in the clinical study due to safety concerns with clinical study procedures
  19. * Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

Contacts and Locations

Principal Investigator

Karamjeet S Sandhu
PRINCIPAL_INVESTIGATOR
City of Hope Medical Center

Study Locations (Sites)

City of Hope Medical Center
Duarte, California, 91010
United States

Collaborators and Investigators

Sponsor: City of Hope Medical Center

  • Karamjeet S Sandhu, PRINCIPAL_INVESTIGATOR, City of Hope Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-12-07
Study Completion Date2026-09-03

Study Record Updates

Study Start Date2023-12-07
Study Completion Date2026-09-03

Terms related to this study

Additional Relevant MeSH Terms

  • Acute Myeloid Leukemia
  • Recurrent Adult Acute Myeloid Leukemia
  • Refractory Acute Myeloid Leukemia
  • Secondary Acute Myeloid Leukemia